| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 147, 1545-1552, Copyright © 1995 by American Society for Investigative Pathology
REGULAR ARTICLES |
D Schadendorf, A Makki, C Stahr, A van Dyck, R Wanner, GL Scheffer, MJ Flens, R Scheper and BM Henz
Department of Dermatology, Virchow Clinics, Humboldt University Berlin, Germany.
Melanoma cells often display a multidrug-resistant phenotype, but the mechanisms involved are largely unknown. We have studied here the recently identified transport-associated proteins, MRP and LRP, and the well-known drug resistance marker P-glycoprotein using a panel of 16 human melanoma cell lines and 71 benign and malignant melanocytic tissue samples. By flow cytometry and immunohistochemistry, expression of P-glycoprotein was not detectable on the protein level in the 10 cell lines analyzed, although by reverse transcriptase polymerase chain reaction, MDR-1 gene expression was demonstrated in 2 of 10 cell lines. In addition, immunohistology revealed P-glycoprotein expression in only 1 of 71 melanocytic lesions. In contrast, MRP was detected in a subset of melanoma cell lines by reverse transcriptase polymerase chain reaction and immunohistology (4 of 10). LRP expression was observed in 8 of 10 melanoma cell lines by immunochemistry and in 10 of 10 by reverse transcriptase polymerase chain reaction. Furthermore, MRP was detected immunohistologically in almost 50% of primary and metastatic melanoma specimens, although no significant differences were found between metastases taken before or after chemotherapy. Expression of LRP was detected in a subset of nevi with nevus cells exhibiting up to 25% positive LRP reactivity. In 13 of 21 primary melanomas and 23 of 37 metastases, more than 25% of tumor cells were stained by the LRP-56 monoclonal antibody. Particularly in the group of metastases with more than 50% of LRP-positive cells, 7 of 11 of the metastases had been previously exposed to chemotherapeutic drugs. Although the expression of membrane transport proteins may explain only the chemoresistance toward lipophilic, natural compounds and not resistance against alkylating agents, the lack of P-glycoprotein expression after chemotherapeutic treatment and the significant expression of MRP and LRP in melanoma cells provide first insights into the drug-resistant phenotype in melanoma. Additional studies analyzing the role of MRP and LRP in chemoresistance of melanoma are warranted.
This article has been cited by other articles:
![]() |
P. Depeille, P. Cuq, S. Mary, I. Passagne, A. Evrard, D. Cupissol, and L. Vian Glutathione S-Transferase M1 and Multidrug Resistance Protein 1 Act in Synergy to Protect Melanoma Cells from Vincristine Effects Mol. Pharmacol., April 1, 2004; 65(4): 897 - 905. [Abstract] [Full Text] |
||||
![]() |
U. Stein, K. Jurchott, M. Schlafke, and P. Hohenberger Expression of Multidrug Resistance Genes MVP, MDR1, and MRP1 Determined Sequentially Before, During, and After Hyperthermic Isolated Limb Perfusion of Soft Tissue Sarcoma and Melanoma Patients J. Clin. Oncol., August 1, 2002; 20(15): 3282 - 3292. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Halaban, R. S. Patton, E. Cheng, S. Svedine, E. S. Trombetta, M. L. Wahl, S. Ariyan, and D. N. Hebert Abnormal Acidification of Melanoma Cells Induces Tyrosinase Retention in the Early Secretory Pathway J. Biol. Chem., April 19, 2002; 277(17): 14821 - 14828. [Abstract] [Full Text] [PDF] |
||||
![]() |
J Georgieva, P Sinha, and D Schadendorf Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions J. Clin. Pathol., March 1, 2001; 54(3): 229 - 235. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Toth, M. M. Vaughan, G. Schwartz, J. S. Winston, B. S. Skenderis II, H. K. Slocum, and Y. M. Rustum Expression of the MRP and MDRI Multidrug Resistance Gene Products in 160 Untreated Human Carcinomas Studied by Immunohistochemical Methods in Formalin-Paraffin Sections International Journal of Surgical Pathology, July 1, 1998; 6(3): 145 - 154. [Abstract] [PDF] |
||||
![]() |
M.L. den Boer, R. Pieters, K.M. Kazemier, M.M.A. Rottier, C.M. Zwaan, G.J.L. Kaspers, G. Janka-Schaub, G. Henze, U. Creutzig, R.J. Scheper, et al. Relationship Between Major Vault Protein/Lung Resistance Protein, Multidrug Resistance-Associated Protein, P-Glycoprotein Expression, and Drug Resistance in Childhood Leukemia Blood, March 15, 1998; 91(6): 2092 - 2098. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |